Sigyn Therapeutics, Inc. (OTCQB: SIGY) announced today that a recent study published in Science Translational Medicine and highlighted by Scientific American provides the first clinical evidence of blood-brain barrier disruption and associated inflammation in living individuals suspected of having Chronic Traumatic Encephalopathy (CTE). The findings could have significant implications for the company's CardioDialysis technology, which is designed to clear inflammatory and pathogenic molecules from the bloodstream.
According to the study, researchers at Trinity College Dublin observed that the blood-brain barrier may remain compromised for decades after athletes retire from contact sports involving repetitive head trauma. When the barrier is leaky, inflammatory molecules and toxins from the bloodstream can enter the brain, triggering neuroinflammation and abnormal tau protein accumulation—a hallmark of CTE. The study also noted that former athletes appeared to exist in a persistent state of chronic hyperinflammation.
The Scientific American article underscores a growing body of evidence linking systemic inflammation to neuroinflammatory disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Sigyn Therapeutics believes that CardioDialysis, which enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules, is uniquely positioned as a potential adjunct therapy for these conditions.
"It is becoming increasingly clear that CardioDialysis may play a meaningful role to slow the progression of neuroinflammatory disorders, particularly in high-risk individuals or during the early stages of disease," said Sigyn Therapeutics CEO Jim Joyce. "The dual reduction of inflammatory and pathogenic factors from the bloodstream could help stabilize the blood-brain barrier, which would limit the leakage of harmful molecules into the brain."
The company is pursuing a strategic transaction focused on using CardioDialysis to reduce systemic inflammation associated with traumatic brain injury (TBI). CardioDialysis integrates plasma separation and therapeutic adsorption within a single device, offering a broad-spectrum approach that could overcome limitations of single-target drugs. The technology is also being explored for sepsis, viral infections, and cardiovascular disease—the latter remaining the company's lead clinical indication.
"This research adds to the rationale for using blood purification to address neuroinflammation," Joyce added. "CardioDialysis could be a game-changer for patients at risk of CTE and other neurodegenerative diseases."
